Ruxolitinib (RUX), an oral JAK inhibitor approved by the FDA for the treatment of myelofibrosis, polycythemia vera, and graft versus host disease works through reducing the abundance of cytokines and growth factor receptors that utilize JAK1 and JAK2. The gene discussed is JAK2; the disease is myelofibrosis.